Goldsmith B J, Wara W M, Wilson C B, Larson D A
Department of Radiation Oncology, School of Medicine, University of California, San Francisco.
J Neurosurg. 1994 Feb;80(2):195-201. doi: 10.3171/jns.1994.80.2.0195.
The authors retrospectively analyzed 140 patients treated at the University of California, San Francisco, from 1967 to 1990 to evaluate the results of radiation therapy (median 5400 cGy) given as an adjuvant to subtotal resection of intracranial meningioma. Of the 140 meningiomas, 117 were benign and 23 were malignant. The median follow-up period was 40 months. The overall survival rate at 5 years was 85% for the benign and 58% for the malignant tumor groups (p = 0.02); the 5-year progression-free survival rates were 89% and 48%, respectively (p = 0.001). For patients with benign meningioma, the 10-year overall and progression-free survival rates were 77%. An improved progression-free survival rate in that group was not related to tumor size but was associated with a younger age (p = 0.01) and treatment after 1980 with innovative technologies (p = 0.002); none of those variables affected the progression-free survival rate in the patients with malignant meningioma. Increased progression-free survival in the benign tumor group was also significantly associated with increasing the minimum radiation dose (p = 0.04). The 5-year progression-free survival rate for patients with benign meningioma treated after 1980 (when computerized tomography or magnetic resonance imaging was used for planning therapy) was 98%, as compared with 77% for patients treated before 1980 (p = 0.002). There were no second central nervous system tumors. Morbidity (3.6%) included sudden blindness or cerebral necrosis and death. When total resection of benign meningioma is not feasible, subtotal resection combined with precise treatment planning techniques and adjuvant radiation therapy can achieve results comparable to those of total resection.
作者回顾性分析了1967年至1990年在加利福尼亚大学旧金山分校接受治疗的140例患者,以评估作为颅内脑膜瘤次全切除辅助治疗的放射治疗(中位剂量5400 cGy)的效果。在这140例脑膜瘤中,117例为良性,23例为恶性。中位随访期为40个月。良性肿瘤组5年总生存率为85%,恶性肿瘤组为58%(p = 0.02);5年无进展生存率分别为89%和48%(p = 0.001)。对于良性脑膜瘤患者,10年总生存率和无进展生存率均为77%。该组无进展生存率的提高与肿瘤大小无关,而与年龄较轻(p = 0.01)以及1980年后采用创新技术治疗有关(p = 0.002);这些变量均未影响恶性脑膜瘤患者的无进展生存率。良性肿瘤组无进展生存率的提高也与增加最小放射剂量显著相关(p = 0.04)。1980年后(采用计算机断层扫描或磁共振成像进行治疗计划时)接受治疗的良性脑膜瘤患者5年无进展生存率为98%,而1980年前接受治疗的患者为77%(p = 0.002)。未出现第二原发性中枢神经系统肿瘤。并发症发生率为3.6%,包括突然失明或脑坏死以及死亡。当无法进行良性脑膜瘤全切除时,次全切除联合精确的治疗计划技术和辅助放射治疗可取得与全切除相当的效果。